Since PIK3CA mutations and PTEN loss/mutation are frequently found in GBM, isoform-selective PI3K inhibitors, especially against p110α and p110β, may have potentials for the treatment of GBM bearing these genetic mutations. The gene discussed is PTEN; the disease is glioblastoma.